|
1
|
Fenton-Ambrose L and Kazerooni EA:
Preventative care: Lung-cancer screens now worth the cost. Nature.
514:352014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kong R, Feng J, Ma Y, Zhou B, Li S, Zhang
W, Jiang J, Zhang J, Qiao Z, Zhang T, et al: Silencing NACK by
siRNA inhibits tumorigenesis in non-small cell lung cancer via
targeting Notch1 signaling pathway. Oncol Rep. 35:2306–2314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brody H: Lung cancer. Nature. 513:S12014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moro-Sibilot D, Smit E, de Castro Carpeño
J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine
K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer
patients with brain metastases treated with first-line
platinum-doublet chemotherapy: Analysis from the European FRAME
study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barnett SA, Downey RJ, Zheng J, Plourde G,
Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of
routine PET imaging to predict response and survival after
induction therapy for non-small cell lung cancer. Ann Thorac Surg.
101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y,
Zhang YP, Hu X and Mao WM: The clinical pathological
characteristics and prognosis of FGFR1 gene amplification in
non-small-cell lung cancer: A meta-analysis. Onco Targets Ther.
9:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim SH, Sun JM, Lee SH, Ahn JS, Park K and
Ahn MJ: Pembrolizumab for the treatment of non-small cell lung
cancer. Expert Opin Biol Ther. 16:397–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Müller B, Bovet M, Yin Y, Stichel D, Malz
M, González-Vallinas M, Middleton A, Ehemann V, Schmitt J, Muley T,
et al: Concomitant expression of far upstream element (FUSE)
binding protein (FBP) interacting repressor (FIR) and its splice
variants induce migration and invasion of non-small cell lung
cancer (NSCLC) cells. J Pathol. 237:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Q, Yue J, Zhang C, Gu X, Chen H and
Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses
epithelial-mesenchymal transition (EMT) and suppresses migration
and invasion in non-small cell lung cancer (NSCLC). Oncotarget.
6:29335–29346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X
and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell
proliferation, migration, and invasion. Acta Biochim Biophys Sin
(Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roth MT, Ivey JL, Esserman DA, Crisp G,
Kurz J and Weinberger M: Individualized medication assessment and
planning: Optimizing medication use in older adults in the primary
care setting. Pharmacotherapy. 33:787–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Solimando DA Jr and Waddell JA: Lenvatinib
and palbociclib. Hosp Pharm. 50:578–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oikonomopoulos G, Aravind P and Sarker D:
Lenvatinib: A potential breakthrough in advanced hepatocellular
carcinoma? Future Oncol. 12:465–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishio M, Horai T, Horiike A, Nokihara H,
Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio
K, et al: Phase 1 study of lenvatinib combined with carboplatin and
paclitaxel in patients with non-small-cell lung cancer. Br J
Cancer. 109:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hutson TE: Targeted therapies for the
treatment of metastatic renal cell carcinoma: Clinical evidence.
Oncologist. 16 (Suppl 2):S14–S22. 2011. View Article : Google Scholar
|
|
16
|
Matsui J and Funahashi Y: Preclinical
biomarker research and patient stratification of molecular target
agents: The anti-angiogenic inhibitor Lenvatinib mesylate (E7080).
Nihon Yakurigaku Zasshi. 142:162–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okamoto K, Kodama K, Takase K, Sugi NH,
Yamamoto Y, Iwata M and Tsuruoka A: Antitumor activities of the
targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against
RET gene fusion-driven tumor models. Cancer Lett. 340:97–103. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuznar W: Lenvatinib extends survival in
metastatic renal-cell carcinoma. Am Health Drug Benefits.
8:182015.(In Japanese). PubMed/NCBI
|
|
19
|
Molina AM, Hutson TE, Larkin J, Gold AM,
Wood K, Carter D, Motzer R and Michaelson MD: A phase 1b clinical
trial of the multi-targeted tyrosine kinase inhibitor lenvatinib
(E7080) in combination with everolimus for treatment of metastatic
renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 73:181–189.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berdeja J, Jagannath S, Zonder J, Badros
A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt
E, et al: Pharmacokinetics and safety of elotuzumab combined with
lenalidomide and dexamethasone in patients with multiple myeloma
and various levels of renal impairment: Results of a phase Ib
study. Clin Lymphoma Myeloma Leuk. 16:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han S, Bui NT, Ho MT, Kim YM, Cho M and
Shin DB: Dexamethasone inhibits TGF-β1-induced cell migration by
regulating the ERK and AKT pathways in human colon cancer cells via
CYR61. Cancer Res Treat. 48:1141–1153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chijiiwa M, Mochizuki S, Kimura T, Abe H,
Tanaka Y, Fujii Y, Shimizu H, Enomoto H, Toyama Y and Okada Y: CCN1
(Cyr61) is overexpressed in human osteoarthritic cartilage and
inhibits ADAMTS-4 (Aggrecanase 1) activity. Arthritis Rheumatol.
67:1557–1567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grazioli S, Gil S, An D, Kajikawa O,
Farnand AW, Hanson JF, Birkland T, Chen P, Duffield J, Schnapp LM,
et al: CYR61 (CCN1) overexpression induces lung injury in mice. Am
J Physiol Lung Cell Mol Physiol. 308:L759–L765. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhuang T, Djemil T, Qi P, Magnelli A,
Stephans K, Videtic G and Xia P: Dose calculation differences
between Monte Carlo and pencil beam depend on the tumor locations
and volumes for lung stereotactic body radiation therapy. J Appl
Clin Med Phys. 14:40112013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang YT, Lan Q, Ponsonnet L, Blanquet M,
Christofori G, Zaric J and Rüegg C: The matricellular protein CYR61
interferes with normal pancreatic islets architecture and promotes
pancreatic neuroendocrine tumor progression. Oncotarget.
7:1663–1674. 2016.PubMed/NCBI
|
|
27
|
Nagashima S, Matsuo S, Takahashi M,
Umemoto Y, Hirano T, Enomoto K, Sakurai K and Amano S:
Effectiveness of lenvatinib for thyroid cancer with lung
metastases-report of a case. Gan To Kagaku Ryoho. 43:2121–2123.
2016.(In Japanese). PubMed/NCBI
|
|
28
|
Li Z, Xu X, Bai L, Chen W and Lin Y:
Epidermal growth factor receptor-mediated tissue transglutaminase
overexpression couples acquired tumor necrosis factor-related
apoptosis-inducing ligand resistance and migration through c-FLIP
and MMP-9 proteins in lung cancer cells. J Biol Chem.
286:21164–21172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH,
Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, et al: Incidence of second
primary malignancies following colorectal cancer: A distinct
pattern of occurrence between colon and rectal cancers and
association of co-morbidity with second primary malignancies in a
population-based cohort of 98,876 patients in Taiwan. Medicine
(Baltimore). 94:e10792015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Charvat H, Sasazuki S, Inoue M, Iwasaki M,
Sawada N, Shimazu T, Yamaji T and Tsugane S; JPHC Study Group, :
Prediction of the 10-year probability of gastric cancer occurrence
in the Japanese population: The JPHC study cohort II. Int J Cancer.
138:320–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim DS, Park KM, Won YS, Kim JY, Lee JK,
Kim JG, Oh ST, Jung SS and Kang WK: Occurrence and prognosis of
symptomatic venous thromboembolism in colorectal cancer surgery
patients. Vasc Specialist Int. 30:49–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gold M, Dunn LB, Phoenix B, Paul SM,
Hamolsky D, Levine JD and Miaskowski C: Co-occurrence of anxiety
and depressive symptoms following breast cancer surgery and its
impact on quality of life. Eur J Oncol Nurs. 20:97–105. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu X, Song Y, Huo R, Zhang J, Sun S, He
Y, Gao H, Zhang M, Sun X, Zhai T, et al: Cyr61 participates in the
pathogenesis of rheumatoid arthritis by promoting proIL-1β
production by fibroblast-like synoviocytes through an AKT-dependent
NF-κB signaling pathway. Clin Immunol. 157:187–197. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sánchez-Bailón MP, Calcabrini A,
Mayoral-Varo V, Molinari A, Wagner KU, Losada JP, Ciordia S, Albar
JP and Martín-Pérez J: Cyr61 as mediator of Src signaling in triple
negative breast cancer cells. Oncotarget. 6:13520–13538. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee YJ, Lee DM and Lee SH: Production of
Cyr61 protein is modulated by extracellular acidification and
PI3K/Akt signaling in prostate carcinoma PC-3 cells. Food Chem
Toxicol. 58:169–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Song Y, Yang J, Gong L, Zhao P,
Zhang Y and Su H: The up-regulation of cysteine-rich protein 61
induced by transforming growth factor beta enhances osteosarcoma
cell migration. Mol Cell Biochem. 384:269–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Villanueva MT: Targeted therapies:
Congratulations, you are still in the running towards becoming
ovarian-next-top treatment. Nat Rev Clin Oncol. 8:5702011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ngeow J, Tan IB and Choo SP: Targeted
therapies in the treatment of gastric cancer. Asia Pac J Clin
Oncol. 7:224–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boss DS, Glen H, Beijnen JH, Keesen M,
Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, et
al: A phase I study of E7080, a multitargeted tyrosine kinase
inhibitor, in patients with advanced solid tumours. Br J Cancer.
106:1598–1604. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsuruoka A, Matsui J, Suzuki T, Koyama N,
Watanabe T and Funahashi Y: Preclinical and clinical researches of
lenvatinib mesylate (Lenvima capsule), a novel antitumor agent
approved for thyroid cancer treatment. Nihon Yakurigaku Zasshi.
146:283–290. 2015.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nakagawa T, Matsushima T, Kawano S,
Nakazawa Y, Kato Y, Adachi Y, Abe T, Semba T, Yokoi A, Matsui J, et
al: Lenvatinib in combination with golvatinib overcomes hepatocyte
growth factor pathway-induced resistance to vascular endothelial
growth factor receptor inhibitor. Cancer Sci. 105:723–730. 2014.
View Article : Google Scholar : PubMed/NCBI
|
